PMC4937691_01
A non-contrast CT image shows a 23x18 mm, well-circumscribed, low-density mass in segment 6 of the liver (A). Dynamic CT images demonstrate the enhancement of the mass in the arterial phase (B) and early washout in the late phase (C)
AOJNMB-3-58-g001.jpg
PMC4937691_01_AOJNMB-3-58-g001.jpg
F1
Computed tomography (CT) images showed a 23x18 mm, well-circumscribed mass in segment 6 of the liver (Figure 1). 18F-FDG PET was performed using a Biograph mCT 64 slice PET/CT scanner.
18F-FDG PET image shows an increased uptake in the liver, with a maximum standardized uptake value of 5.04 (A). Fused PET/CT image clearly shows that the accumulation corresponds to a liver mass (B)
AOJNMB-3-58-g002.jpg
PMC4937691_01_AOJNMB-3-58-g002.jpg
F2
The dose of 18F-FDG was 370 MBq. 18F-FDG PET and fused PET/CT images showed increased uptake in the hepatic mass (Figure 2).
The image of the resected specimen shows a 22x20 mm solid mass (A). In Ki-67 immunohistochemistry, Ki-67 positive nuclei demonstrate a proliferation rate of 2% (B). Tumor cells proliferate in nests or trabeculae, presenting a focal rosette pattern. The tumor cells are immunoreactive for chromogranin A (C) and synaptophysin (D)
AOJNMB-3-58-g003.jpg
PMC4937691_01_AOJNMB-3-58-g003.jpg
F3
Histological and immunohistochemistry of the tumor confirmed a NET grade 1 (Figure 3).